Pfizer Inc (NYSE:PFE) shares traded -0.75% lower at $26.42 on Wall Street last session.
PFE stock price is now -0.73% away from the 50-day moving average and -5.43% away from the 200-day moving average. The market capitalization of the company currently stands at $150.06B.
On November 15, 2024, Wolfe Research recently initiated its ‘Underperform’ rating on the stock quoting a target price of $25, while ‘Citigroup’ rates the stock as ‘Neutral’
In other news, Gottlieb Scott, Director bought 1,000 shares of the company’s stock on Oct 30 ’24. The stock was bought for $28,240 at an average price of $28.24. Upon completion of the transaction, the Director now directly owns 10,000 shares in the company, valued at $0.26 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 13 ’24, SVP & Controller DAMICO JENNIFER B. sold 5,154 shares of the business’s stock. A total of $147,714 was realized by selling the stock at an average price of $28.66. This leaves the insider owning 8,582 shares of the company worth $0.23 million. A total of 0.03% of the company’s stock is owned by insiders.
During the past 12 months, Pfizer Inc has had a low of $24.48 and a high of $31.54. As of last week, the company has a debt-to-equity ratio of 0.73, a current ratio of 1.00, and a quick ratio of 0.73. According to the stock market information, the enterprise value for the company is $207985868800, which is based on a 35.52 price-to-earnings ratio, a 4.70 price-to-earnings-growth ratio, and a beta of 0.62. The fifty day moving average price for PFE is $26.6146 and a two-hundred day moving average price translates $27.93725 for the stock.
The latest earnings results from Pfizer Inc (NYSE: PFE) was released for 2024-09-29. The net profit margin was 7.11% and return on equity was 4.52% for PFE. The company reported revenue of $17.7 billion for the quarter, compared to $13.49 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 31.21 percent.
